Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Jackson

Showing results (151-160 of 170) with videos related to

Pageof 17
Sort By:
The Lancet. Oncology|March 6, 2017
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trialGary Middleton, Daniel H Palmer, William Greenhalf, et al.
The Lancet. Oncology|April 14, 2022
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trialSyed A Hussain, Jason F Lester, Richard Jackson, et al.
Pancreas|December 2, 2014
Incidence of post-ERCP pancreatitis from direct pancreatic juice collection in hereditary pancreatitis and familial pancreatic cancer before and after the introduction of prophylactic pancreatic stents and rectal diclofenacJames A Nicholson, William Greenhalf, Richard Jackson, et al.
Journal of the National Cancer Institute|December 1, 2025
NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancerDylan Williams, Chandni Patel, Kate Murray, et al.
Haematologica|December 1, 2020
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trialAndrew R Pettitt, Richard Jackson, Silvia Cicconi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trialAndrew R Pettitt, Richard Jackson, Stacey Carruthers, et al.
Cancers|November 27, 2021
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNAKaren Aughton, Nils O Elander, Anthony Evans, et al.
British Journal of Haematology|June 13, 2024
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapyYeong Jer Lim, Victoria Ward, Anthony Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 studyJuan W Valle, Daniel Palmer, Richard Jackson, et al.
Nutrients|September 14, 2024
Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria SeverityAlex Pinto, Kirsten Ahring, Manuela Ferreira Almeida, et al.
Pageof 17

Showing results (151-160 of 170) with videos related to

Sort By:
Pageof 17
The Lancet. Oncology|March 6, 2017
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trialGary Middleton, Daniel H Palmer, William Greenhalf, et al.
The Lancet. Oncology|April 14, 2022
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trialSyed A Hussain, Jason F Lester, Richard Jackson, et al.
Pancreas|December 2, 2014
Incidence of post-ERCP pancreatitis from direct pancreatic juice collection in hereditary pancreatitis and familial pancreatic cancer before and after the introduction of prophylactic pancreatic stents and rectal diclofenacJames A Nicholson, William Greenhalf, Richard Jackson, et al.
Journal of the National Cancer Institute|December 1, 2025
NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancerDylan Williams, Chandni Patel, Kate Murray, et al.
Haematologica|December 1, 2020
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trialAndrew R Pettitt, Richard Jackson, Silvia Cicconi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trialAndrew R Pettitt, Richard Jackson, Stacey Carruthers, et al.
Cancers|November 27, 2021
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNAKaren Aughton, Nils O Elander, Anthony Evans, et al.
British Journal of Haematology|June 13, 2024
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapyYeong Jer Lim, Victoria Ward, Anthony Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 studyJuan W Valle, Daniel Palmer, Richard Jackson, et al.
Nutrients|September 14, 2024
Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria SeverityAlex Pinto, Kirsten Ahring, Manuela Ferreira Almeida, et al.
Pageof 17